Cyclothiazide Induces Robust Epileptiform Activity in Rat Hippocampal Neurons Both in Vitro and in Vivo

Total Page:16

File Type:pdf, Size:1020Kb

Cyclothiazide Induces Robust Epileptiform Activity in Rat Hippocampal Neurons Both in Vitro and in Vivo http://www.paper.edu.cn 中国科技论文在线 J Physiol 571.3 (2006) pp 605–618 605 Cyclothiazide induces robust epileptiform activity in rat hippocampal neurons both in vitro and in vivo Jinshun Qi1, Yun Wang2, Min Jiang1, Philippa Warren2 and Gong Chen1 1Department of Biology, The Pennsylvania State University, University Park, PA 16802, USA 2Lilly Research Centre, Eli Lilly & Co Ltd, Sunninghill Road, Windlesham, Surrey, GU20 6PH, UK Cyclothiazide (CTZ) is a potent blocker of AMPA receptor desensitization. We have recently demonstrated that CTZ also inhibits GABAA receptors. Here we report that CTZ induces robust epileptiform activity in hippocampal neurons both in vitro and in vivo. We first found that chronic treatment of hippocampal cultures with CTZ (5 μM, 48 h) results in epileptiform activity in the majority of neurons (80%). The epileptiform activity lasts more than 48 h after washing off CTZ, suggesting a permanent change of the neural network properties after CTZ treatment. We then demonstrated in in vivo recordings that injection of CTZ (5 μmol in 5 μl) into the lateral ventricles of anaesthetized rats also induces spontaneous epileptiform activity in the hippocampal CA1 region. The epileptogenic effect of CTZ is probably due to its enhancing glutamatergic neurotransmission as shown by increasing the frequency and decay time of mEPSCs, and simultaneously inhibiting GABAergic neurotransmission by reducing the frequency of mIPSCs. Comparing to a well-known epileptogenic agent kainic acid (KA), CTZ affects neuronal activity mainly through modulating synaptic transmission without significant change of the intrinsic membrane excitability. Unlike KA, which induces significant cell death in hippocampal cultures, CTZ treatment does not result in any apparent neuronal death. Therefore, the CTZ-induced epilepsy model may provide a novel research tool to elucidate the molecular and cellular mechanisms of epileptogenesis without any complication from drug-induced cell death. The long-lasting epileptiform activity after CTZ washout may also make it a very useful model in screening antiepileptic drugs. (Resubmitted 17 December 2005; accepted after revision 12 January 2006; first published online 19 January 2006) Corresponding author G. Chen: Assistant Professor of Neurobiology, Department of Biology, 201 Life Sciences Building, Huck Institutes of Life Sciences, The Pennsylvania State University, University Park, PA 16802, USA. Email: [email protected] Cyclothiazide (CTZ) was originally known as a diuretic inhibition balance toward hyperexcitation. We therefore drug with antihypertensive effects (Julius et al. 1962; hypothesize that CTZ may work as an epileptogenic agent Schvartz et al. 1962). It was later found that CTZ is a potent to induce epileptiform activity in central neurons. blocker of AMPA receptor desensitization (Patneau et al. To test our hypothesis, we treated hippocampal 1993; Trussell et al. 1993; Yamada & Tang, 1993; Zorumski CA1–CA3 cultures with CTZ either in short-term et al. 1993; Barnes-Davies & Forsythe, 1995; Mennerick duration but high concentration (1–2 h, 20–50 μm), or & Zorumski, 1995). CTZ also increases presynaptic chronically with low concentration (2–10 days, 5 μm). glutamate release (Diamond & Jahr, 1995; Bellingham & In both conditions, CTZ consistently induced robust Walmsley, 1999; Ishikawa & Takahashi, 2001). Our recent epileptiform activity in cultured hippocampal neurons. work has further demonstrated that CTZ can directly More importantly, the epileptiform activity induced by inhibit GABAA receptors as shown by both whole-cell and chronic CTZ treatment lasts more than 48 h after washing single-channel experiments (Deng & Chen, 2003). Thus, off CTZ, suggesting a substantial change of neural CTZ has a unique characteristic in acting simultaneously network activities after CTZ treatment. To test whether on two prominent synaptic transmission systems: it the epileptogenic effect of CTZ is limited to in vitro significantly enhances excitatory glutamatergic neuro- cultures, we injected CTZ into the lateral ventricles of transmission while suppressing inhibitory GABAergic anaesthetized rats, and found that CTZ can also induce neurotransmission. The net effect of CTZ on a neural spontaneous epileptiform activity in the hippocampal network will be a significant tilt of the excitation– CA1 region in vivo. The epileptogenic effect of CTZ C 2006 The Authors. Journal compilation C 2006 The Physiological Society DOI: 10.1113/jphysiol.2005.103812 转载 中国科技论文在线 http://www.paper.edu.cn 606 J. Qi and others J Physiol 571.3 is attributable to its modulation of glutamatergic and MiniAnalysis software (Synaptosoft). All data were GABAergic neurotransmission without any significant expressed as mean ± s.e.m. and Student’s t test was used change of the intrinsic membrane properties, because the for statistical analysis. spiking threshold and action potential firing rate did not Large depolarization shift resembling paroxysmal change after CTZ treatment. In comparison to KA, which depolarization shift is defined here as ≥10 mV shows strong neurotoxicity, chronic CTZ treatment does depolarization and ≥300 ms in duration. An epileptiform not induce any significant cell death. Thus, a CTZ-induced burst is defined by at least five consecutive action epilepsy model may serve as a useful tool in epilepsy potentials overlaying on top of the large depolarization research with minimal side-effects on neuronal survival. shift. When quantifying the percentage of neurons showing epileptiform activity, the criterion is at least four repeated epileptiform bursts occurring during 30 min of Methods recording. Pyramidal shape neurons were selected for Cell culture recordings. For each neuron recorded after kainic acid (KA) or CTZ treatment, epileptiform discharges were first Hippocampal cultures were prepared from new born verified under current-clamp conditions before recording Sprague-Dawley rats (P0–P1) as previously described miniature and whole-cell currents under voltage-clamp (Deng & Chen, 2003; Chen et al. 2004). In brief, the conditions. hippocampal CA1–CA3 region was dissected out and incubated for 30 min in 0.05% trypsin–EDTA solution. After enzyme treatment, tissue blocks were triturated In vivo recordings gently, and dissociated cells were plated onto a mono- In vivo experiments were performed using adult male layer of astrocytes. The culture medium contained Sprague-Dawley rats (250–350 g body weight) and 500 ml MEM (Gibco), 5% fetal bovine serum (Hyclone), anaesthetized with urethane (1.2 g kg−1) under the md m 10 ml B-27, 100 mg NaHCO3,20m -glucose, 0.5 m Animals (Scientific Procedures) Act 1986 and approved l −1 -glutamine, and 25 u ml penicillin/streptomycin. Cells by the local ethics committee. At the end of experiments, were maintained in 5% CO2 incubator for 2–3 weeks. The animals were killed with an overdose of urethane. adult rats were killed with CO2,and new-born pups were The femoral artery was cannulated to allow arterial decapitated in accordance with animal protocols approved blood pressure to be monitored. Animals were then bytheIACUCcommitteeinPennsylvaniaStateUniversity. mounted in a stereotaxic frame. A drill hole was made on the skull above the left side of the lateral ventricle (0.3 mm posterior to bregma, 1.3 mm lateral to the midline). Electrophysiology A guide cannula was then placed 4 mm below the skull Whole-cell recordings were performed in current- or surface for drug delivery, and secured by the dental voltage-clamp mode using a MultiClamp 700 A amplifier cement. For recording and stimulating, a large burr hole (Axon Instruments). Patch pipettes were pulled from was made in the left side of the incised skull above the borosilicate glass and fire polished (2–4 M). The hippocampal area, and the dura was pierced and removed. recording chamber was continuously perfused with For recording in the CA1 pyramidal cell layer, a tungsten a bath solution consisting of (mm): 128 NaCl, 30 electrode (0.5 M) was placed 3.5–4.2 mm posterior to Glucose, 25 Hepes, 5 KCl, 2 CaCl2, 1 MgCl2, pH 7.3 bregma, 2.0–3.0 mm lateral to the midline. The depth of adjusted with NaOH. The pipette solution for most of the recording electrode was approximately 2.0–2.5 mm the experiments, such as recording action potentials, below the brain surface as determined by the sudden mEPSCs, and glutamate receptor responses, contained change of electrical noise and the shape of the evoked field (mm): 125 K-gluconate, 10 KCl, 2 EGTA, 10 Hepes, excitatory postsynaptic potential (fEPSPs) and population 10 Tris-phosphocreatine, 4 MgATP, 0.5 Na2GTP, pH 7.3 spike. A bipolar stimulating electrode was placed close adjusted with KOH. For mIPSCs and GABA-induced to the CA3 region in order to stimulate the Shaffer currents, pipettes were filled with (mm): 135 KCl, 10 collateral (3.8–4.5 mm posterior to bregma, 3.5–4.0 mm Tris-phosphocreatine, 2 EGTA, 10 Hepes, 4 MgATP, 0.5 lateral to the midline, and 3.0–3.8 mm below the brain Na2GTP, pH 7.3 adjusted with KOH. The series resistance surface). Once both electrodes were in the right place, the was typically 10–20 M and partially compensated by fEPSPs and population spike (PS) were monitored for at 30–50%. The membrane potential was held around least 30 min until a stable recording was achieved. The −70 mV in both voltage-clamp and current-clamp stimulation frequency was set at once per minute with recordings. Data were acquired using pClamp 9 software, single biphasic square-wave pulses of 0.2 ms duration and sampled at 2–10 kHz, and filtered at 1 kHz. Off-line 700–900 μA (supramaximal, determined by input–output analysis was done with Clampfit 9 software (Axon curve). In between stimulations, the baseline activity was Instruments). Miniature events were analysed using recorded for evidence of spontaneous activity. Following a C 2006 The Authors. Journal compilation C 2006 The Physiological Society 中国科技论文在线 http://www.paper.edu.cn J Physiol 571.3 Cyclothiazide induces epileptiform activity 607 30 min recorded baseline of all responses, drugs or vehicles glutamatergic neurotransmission (Patneau et al.
Recommended publications
  • NINDS Custom Collection II
    ACACETIN ACEBUTOLOL HYDROCHLORIDE ACECLIDINE HYDROCHLORIDE ACEMETACIN ACETAMINOPHEN ACETAMINOSALOL ACETANILIDE ACETARSOL ACETAZOLAMIDE ACETOHYDROXAMIC ACID ACETRIAZOIC ACID ACETYL TYROSINE ETHYL ESTER ACETYLCARNITINE ACETYLCHOLINE ACETYLCYSTEINE ACETYLGLUCOSAMINE ACETYLGLUTAMIC ACID ACETYL-L-LEUCINE ACETYLPHENYLALANINE ACETYLSEROTONIN ACETYLTRYPTOPHAN ACEXAMIC ACID ACIVICIN ACLACINOMYCIN A1 ACONITINE ACRIFLAVINIUM HYDROCHLORIDE ACRISORCIN ACTINONIN ACYCLOVIR ADENOSINE PHOSPHATE ADENOSINE ADRENALINE BITARTRATE AESCULIN AJMALINE AKLAVINE HYDROCHLORIDE ALANYL-dl-LEUCINE ALANYL-dl-PHENYLALANINE ALAPROCLATE ALBENDAZOLE ALBUTEROL ALEXIDINE HYDROCHLORIDE ALLANTOIN ALLOPURINOL ALMOTRIPTAN ALOIN ALPRENOLOL ALTRETAMINE ALVERINE CITRATE AMANTADINE HYDROCHLORIDE AMBROXOL HYDROCHLORIDE AMCINONIDE AMIKACIN SULFATE AMILORIDE HYDROCHLORIDE 3-AMINOBENZAMIDE gamma-AMINOBUTYRIC ACID AMINOCAPROIC ACID N- (2-AMINOETHYL)-4-CHLOROBENZAMIDE (RO-16-6491) AMINOGLUTETHIMIDE AMINOHIPPURIC ACID AMINOHYDROXYBUTYRIC ACID AMINOLEVULINIC ACID HYDROCHLORIDE AMINOPHENAZONE 3-AMINOPROPANESULPHONIC ACID AMINOPYRIDINE 9-AMINO-1,2,3,4-TETRAHYDROACRIDINE HYDROCHLORIDE AMINOTHIAZOLE AMIODARONE HYDROCHLORIDE AMIPRILOSE AMITRIPTYLINE HYDROCHLORIDE AMLODIPINE BESYLATE AMODIAQUINE DIHYDROCHLORIDE AMOXEPINE AMOXICILLIN AMPICILLIN SODIUM AMPROLIUM AMRINONE AMYGDALIN ANABASAMINE HYDROCHLORIDE ANABASINE HYDROCHLORIDE ANCITABINE HYDROCHLORIDE ANDROSTERONE SODIUM SULFATE ANIRACETAM ANISINDIONE ANISODAMINE ANISOMYCIN ANTAZOLINE PHOSPHATE ANTHRALIN ANTIMYCIN A (A1 shown) ANTIPYRINE APHYLLIC
    [Show full text]
  • DIURETICS Diuretics Are Drugs That Promote the Output of Urine Excreted by the Kidneys
    DIURETICS Diuretics are drugs that promote the output of urine excreted by the Kidneys. The primary action of most diuretics is the direct inhibition of Na+ transport at one or more of the four major anatomical sites along the nephron, where Na+ reabsorption takes place. The increased excretion of water and electrolytes by the kidneys is dependent on three different processes viz., glomerular filtration, tubular reabsorption (active and passive) and tubular secretion. Diuretics are very effective in the treatment of Cardiac oedema, specifically the one related with congestive heart failure. They are employed extensively in various types of disorders, for example, nephritic syndrome, diabetes insipidus, nutritional oedema, cirrhosis of the liver, hypertension, oedema of pregnancy and also to lower intraocular and cerebrospinal fluid pressure. Therapeutic Uses of Diuretics i) Congestive Heart Failure: The choice of the diuretic would depend on the severity of the disorder. In an emergency like acute pulmonary oedema, intravenous Furosemide or Sodium ethacrynate may be given. In less severe cases. Hydrochlorothiazide or Chlorthalidone may be used. Potassium-sparing diuretics like Spironolactone or Triamterene may be added to thiazide therapy. ii) Essential hypertension: The thiazides usually sever as primary antihypertensive agents. They may be used as sole agents in patients with mild hypertension or combined with other antihypertensives in more severe cases. iii) Hepatic cirrhosis: Potassium-sparing diuretics like Spironolactone may be employed. If Spironolactone alone fails, then a thiazide diuretic can be added cautiously. Furosemide or Ethacrymnic acid may have to be used if the oedema is regractory, together with spironolactone to lessen potassium loss. Serum potassium levels should be monitored periodically.
    [Show full text]
  • Subpallial Origin of a Population of Projecting Pioneer Neurons During Corticogenesis
    Subpallial origin of a population of projecting pioneer neurons during corticogenesis Javier Morante-Oria*†‡, Alan Carleton*‡, Barbara Ortino†§, Eric J. Kremer¶, Alfonso Faire´ n†ʈ, and Pierre-Marie Lledo*ʈ** *Laboratory of Perception and Memory, Centre National de la Recherche Scientifique, Unite´de Recherche Associe´e 2182, Pasteur Institute, 25 Rue du Docteur Roux, 75724 Paris, France; †Instituto de Neurociencias, Consejo Superior de Investigaciones Cientı´ficas,Universidad Miguel Herna´ndez, 03550 San Juan de Alicante, Spain; §Dipartimento Neurofisiologia Sperimentale, Istituto ‘‘C. Besta’’, Via Celoria 11, 20133 Milan, Italy; and ¶Centre National de la Recherche Scientifique, Unite´Mixte de Recherche 5535, 1919 Route du Monde, 34293 Montpellier, France Communicated by D. Carleton Gajdusek, Centre National de la Recherche Scientifique, Gif-sur-Yvette, France, June 16, 2003 (received for review February 17, 2003) Pyramidal neurons of the mammalian cerebral cortex are gener- reliable markers of such neurons. We show that MZ pioneer ated in the ventricular zone of the pallium whereas the subpallium neurons migrate tangentially to the MZ from subpallial sources. provides the cortex with inhibitory interneurons. The marginal We demonstrate that such a migration is reelin-dependent and, zone contains a subpial stream of migratory interneurons and two in addition, that reelin controls the arrival of MGE-derived different classes of transient neurons, the pioneer neurons pro- interneurons to the CP during early corticogenesis. vided with corticofugal axons, and the reelin-expressing Cajal– Retzius cells. We found in cultured slices that the medial ganglionic Materials and Methods eminence provides the reelin-negative pioneer neurons of the Organotypic Slices. Brains were obtained from embryos of preg- marginal zone.
    [Show full text]
  • LP-BM5 Virus–Infected Mice Produce Activating Autoantibodies to the AMPA Receptor
    LP-BM5 virus–infected mice produce activating autoantibodies to the AMPA receptor Elena Koustova, … , Michael A. Rogawski, Anthony S. Basile J Clin Invest. 2001;107(6):737-744. https://doi.org/10.1172/JCI11500. Article Autoantibodies to α-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA) receptors may contribute to chronic hyperexcitability syndromes and neurodegeneration, but their origin is unclear. We examined LP-BM5 murine leukemia virus–infected mice, which manifest excitotoxic brain lesions and hypergammaglobulinemia, for the presence of AMPA- receptor Ab’s. Endogenous IgG accumulated upon neurons in the neocortex and caudate/putamen of infected mice and interacted with native and recombinant AMPA-receptor subunits with the following relative abundance: GluR3 ≥ GluR1 > GluR2 = GluR4, as determined by immunoprecipitation. In a radioligand assay, IgG preparations from infected mice specifically inhibited [3H]AMPA binding to receptors in brain homogenates, an activity that was lost after preadsorbing the IgG preparation to immobilized LP-BM5 virus. These IgGs also evoked currents when applied to hippocampal pyramidal neurons or to damaged cerebellar granule neurons. These currents could be blocked using any of several AMPA receptor antagonists. Thus, anti–AMPA-receptor Ab’s can be produced as the result of a virus infection, in part through molecular mimicry. These Ab’s may alter neuronal signaling and contribute to the neurodegeneration observed in these mice, actions that may be curtailed by the use of AMPA-receptor antagonists. Find the latest version: https://jci.me/11500/pdf LP-BM5 virus–infected mice produce activating autoantibodies to the AMPA receptor Elena Koustova,1 Yoshitatsu Sei,2 Linda Fossom,1 Mei-Ling Wei,3 Peter N.R.
    [Show full text]
  • Marrakesh Agreement Establishing the World Trade Organization
    No. 31874 Multilateral Marrakesh Agreement establishing the World Trade Organ ization (with final act, annexes and protocol). Concluded at Marrakesh on 15 April 1994 Authentic texts: English, French and Spanish. Registered by the Director-General of the World Trade Organization, acting on behalf of the Parties, on 1 June 1995. Multilat ral Accord de Marrakech instituant l©Organisation mondiale du commerce (avec acte final, annexes et protocole). Conclu Marrakech le 15 avril 1994 Textes authentiques : anglais, français et espagnol. Enregistré par le Directeur général de l'Organisation mondiale du com merce, agissant au nom des Parties, le 1er juin 1995. Vol. 1867, 1-31874 4_________United Nations — Treaty Series • Nations Unies — Recueil des Traités 1995 Table of contents Table des matières Indice [Volume 1867] FINAL ACT EMBODYING THE RESULTS OF THE URUGUAY ROUND OF MULTILATERAL TRADE NEGOTIATIONS ACTE FINAL REPRENANT LES RESULTATS DES NEGOCIATIONS COMMERCIALES MULTILATERALES DU CYCLE D©URUGUAY ACTA FINAL EN QUE SE INCORPOR N LOS RESULTADOS DE LA RONDA URUGUAY DE NEGOCIACIONES COMERCIALES MULTILATERALES SIGNATURES - SIGNATURES - FIRMAS MINISTERIAL DECISIONS, DECLARATIONS AND UNDERSTANDING DECISIONS, DECLARATIONS ET MEMORANDUM D©ACCORD MINISTERIELS DECISIONES, DECLARACIONES Y ENTEND MIENTO MINISTERIALES MARRAKESH AGREEMENT ESTABLISHING THE WORLD TRADE ORGANIZATION ACCORD DE MARRAKECH INSTITUANT L©ORGANISATION MONDIALE DU COMMERCE ACUERDO DE MARRAKECH POR EL QUE SE ESTABLECE LA ORGANIZACI N MUND1AL DEL COMERCIO ANNEX 1 ANNEXE 1 ANEXO 1 ANNEX
    [Show full text]
  • Customs Tariff - Schedule
    CUSTOMS TARIFF - SCHEDULE 99 - i Chapter 99 SPECIAL CLASSIFICATION PROVISIONS - COMMERCIAL Notes. 1. The provisions of this Chapter are not subject to the rule of specificity in General Interpretative Rule 3 (a). 2. Goods which may be classified under the provisions of Chapter 99, if also eligible for classification under the provisions of Chapter 98, shall be classified in Chapter 98. 3. Goods may be classified under a tariff item in this Chapter and be entitled to the Most-Favoured-Nation Tariff or a preferential tariff rate of customs duty under this Chapter that applies to those goods according to the tariff treatment applicable to their country of origin only after classification under a tariff item in Chapters 1 to 97 has been determined and the conditions of any Chapter 99 provision and any applicable regulations or orders in relation thereto have been met. 4. The words and expressions used in this Chapter have the same meaning as in Chapters 1 to 97. Issued January 1, 2019 99 - 1 CUSTOMS TARIFF - SCHEDULE Tariff Unit of MFN Applicable SS Description of Goods Item Meas. Tariff Preferential Tariffs 9901.00.00 Articles and materials for use in the manufacture or repair of the Free CCCT, LDCT, GPT, UST, following to be employed in commercial fishing or the commercial MT, MUST, CIAT, CT, harvesting of marine plants: CRT, IT, NT, SLT, PT, COLT, JT, PAT, HNT, Artificial bait; KRT, CEUT, UAT, CPTPT: Free Carapace measures; Cordage, fishing lines (including marlines), rope and twine, of a circumference not exceeding 38 mm; Devices for keeping nets open; Fish hooks; Fishing nets and netting; Jiggers; Line floats; Lobster traps; Lures; Marker buoys of any material excluding wood; Net floats; Scallop drag nets; Spat collectors and collector holders; Swivels.
    [Show full text]
  • Presented By: Dr. Joohee Pradhan Assistant Professor Department of Pharmaceutical Sciences, MLSU, Udaipur
    Presented By: Dr. Joohee Pradhan Assistant Professor Department of Pharmaceutical Sciences, MLSU, Udaipur OUTLINE • Introduction and Definition • Relevant Physiology of Urine Formation • Classification: different ways • Carbonic anhydrase inhibitors: Acetazolamide*, Methazolamide, Dichlorphenamide. • Thiazides: Chlorthiazide*, Hydrochlorothiazide, Hydroflumethiazide, Cyclothiazide, • Loop diuretics: Furosemide*, Bumetanide, Ethacrynic acid. • Potassium sparing Diuretics: Spironolactone, Triamterene, Amiloride. • Osmotic Diuretics: Mannitol 2 Introduction and Definition • Diuretics (natriuretics) are drugs which cause a net loss of Na+ and water in urine and hence increase the urine output (or) urine volume. • The primary action of most diuretics is the direct inhibition of Na+ reabsorption (increased excretion) at one or more of the four major sites along the nephron. • An increased Na+ excretion is accompanied by anion like Cl- Since NaCl is the major determinant of extracellular fluid volume; Diuretics reduce extracellular fluid volume (decrease in oedema) by decreasing total body NaCl content. 3 Introduction and Definition • Diuretics are very effective in the treatment of conditions like: o chronic heart failure o nephrotic syndrome o chronic hepatic diseases o hypertension o Pregnancy associated oedema o Cirrhosis of the liver. 4 Relevant Physiology of Urine Formation • Kidneys are the organs responsible for urine formation. Two important functions of the kidney are: o To maintain a homeostatis balance of electrolytes and water. o To excrete water soluble end products of metabolites. • Each kidney contains approximately one million nephrons and is capable of forming urine independently. • Urine formation starts from glomerular filtration (g.f.) in a prodigal way. • Normally, about 180 L of fluid is filtered everyday: all soluble constituents of blood minus the plasma proteins (along with substances bound to them) and lipids, are filtered at the glomerulus.
    [Show full text]
  • Using Medications, Cosmetics, Or Eating Certain Foods Can Increase Sensitivity to Ultraviolet Radiation
    USING MEDICATIONS, COSMETICS, OR EATING CERTAIN FOODS CAN INCREASE SENSITIVITY TO ULTRAVIOLET RADIATION. INDIVIDUALS SHOULD CONSULT A PHYSICIAN BEFORE USING A SUNLAMP, IF THEY ARE TAKING MEDICATIONS. THE ITEMS LISTED ARE POTENTIAL PHOTOSENSITIZING AGENTS THAT MAY INCREASE SENSITIVITY TO ULTRAVIOLET LIGHT THAT MAY RESULT IN A PHOTOTOXIC OR PHOTOALLERGIC RESPONSES. PHOTOSENSITIZING MEDICATIONS Acetazolamide Amiloride+Hydrochlorothizide Amiodarone Amitriptyline Amoxapine Astemizole Atenolol+Chlorthalidone Auranofin Azatadine (Optimine) Azatidine+Pseudoephedrine Bendroflumethiazide Benzthiazide Bromodiphenhydramine Bromopheniramine Captopril Captopril+Hydrochlorothiazide Carbaamazepine Chlordiazepoxide+Amitriptyline Chlorothiazide Chlorpheniramine Chlorpheniramin+DPseudoephedrine Chlorpromazine Chlorpheniramine+Phenylopropanolamine Chlorpropamide Chlorprothixene Chlorthalidone Chlorthalidone+Reserpine Ciprofloxacin Clemastine Clofazime ClonidineChlorthalisone+Coal Tar Coal Tar Contraceptive (oral) Cyclobenzaprine Cyproheptadine Dacarcazine Danazol Demeclocycline Desipramine Dexchlorpheniramine Diclofenac Diflunisal Ditiazem Diphenhydramine Diphenylpyraline Doxepin Doxycycline Doxycycline Hyclate Enalapril Enalapril+Hydrochlorothiazide Erythromycin Ethylsuccinate+Sulfisoxazole Estrogens Estrogens Ethionamide Etretinate Floxuridine Flucytosine Fluorouracil Fluphenazine Flubiprofen Flutamide Gentamicin Glipizide Glyburide Gold Salts (compounds) Gold Sodium Thiomalate Griseofulvin Griseofulvin Ultramicrosize Griseofulvin+Hydrochlorothiazide Haloperidol
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2003/0068365A1 Suvanprakorn Et Al
    US 2003.0068365A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2003/0068365A1 Suvanprakorn et al. (43) Pub. Date: Apr. 10, 2003 (54) COMPOSITIONS AND METHODS FOR Related U.S. Application Data ADMINISTRATION OF ACTIVE AGENTS USING LIPOSOME BEADS (60) Provisional application No. 60/327,643, filed on Oct. 5, 2001. (76) Inventors: Pichit Suvanprakorn, Bangkok (TH); Tanusin Ploysangam, Bangkok (TH); Publication Classification Lerson Tanasugarn, Bangkok (TH); Suwalee Chandrkrachang, Bangkok (51) Int. Cl." .......................... A61K 9/127; A61K 35/78 (TH); Nardo Zaias, Miami Beach, FL (52) U.S. Cl. ............................................ 424/450; 424/725 (US) (57) ABSTRACT Correspondence Address: Law Office of Eric G. Masamori Compositions and methods for administration of active 6520 Ridgewood Drive agents encapsulated within liposome beads to enable a wider Castro Valley, CA 94.552 (US) range of delivery vehicles, to provide longer product shelf life, to allow multiple active agents within the composition, (21) Appl. No.: 10/264,205 to allow the controlled use of the active agents, to provide protected and designable release features and to provide (22) Filed: Oct. 3, 2002 Visual inspection for damage and inconsistency. US 2003/0068365A1 Apr. 10, 2003 COMPOSITIONS AND METHODS FOR toxic degradation of the products, leakage of the drug from ADMINISTRATION OF ACTIVE AGENTS USING the liposome and the modifications of the Size and morphol LPOSOME BEADS ogy of the phospholipid liposome vesicles through aggre gation and fusion. Liposome vesicles are known to be CROSS REFERENCE TO OTHER thermodynamically relatively unstable at room temperature APPLICATIONS and can Spontaneously fuse into larger, leSS Stable altered liposome forms.
    [Show full text]
  • TEXAS RACING COMMISSION January 28, 2021 To
    TEXAS RACING COMMISSION P. O. Box 12080, Austin, Texas 78711-2080 8505 Cross Park Drive, Suite 110, Austin, Texas 78754-4552 Phone (512) 833-6699 Fax (512) 833-6907 www.txrc.texas.gov January 28, 2021 To: Stewards, Commission Veterinarians, Test Barn Supervisors, Practicing Veterinarians, Owners, and Trainers From: Chuck Trout, Executive Director Re: Effective February 25, 2021 changes to the following documents: • Permissible Levels of Therapeutic Medications and Naturally Occurring Substances • Equine Medication Classification Policy and Penalty Guidelines • Equine Medication Classification List. This memo is to provide notice that the above listed documents are to be replaced effective this date. The changes include, but are not limited to: • Changes to the list of Permissible Levels of Therapeutic Medications and Naturally Occurring Substances; • Changes to the Equine Medication Classification Policy and Penalty Guidelines; • Changes to the Equine Medication Classification List. These documents are subject to further revision at any time. Test Barn Supervisors - please post this memo and the revised documents in the test barn as soon as possible. Also, please distribute copies of the Permissible Levels of Therapeutic Medications and Naturally Occurring Substances and Equine Medication Classification List to the practicing veterinarians at your racetrack. Licensing Staff - please post this memo and the revised documents where they may be viewed by the public as soon as possible. Copies of these documents will be made available on the Commission's website at http://www.txrc.texas.gov. Attachments: Permissible Levels of Therapeutic Medications and Naturally Occurring Substances Equine Medication Classification Policy and Penalty Guidelines Equine Medication Classification List TEXAS RACING COMMISSION P.
    [Show full text]
  • Download Product Insert (PDF)
    Product Information Cyclothiazide Item No. 16335 CAS Registry No.: 2259-96-3 Formal Name: 1, 1- dioxide 3- bicyclo[2.2.1] hept- 5- en- 2- yl- 6- chloro- 3, 4- dihydro-2H- 1, 2, H 4- benzothiadiazine- 7- sulfonamide N Synonym: Doburil Cl MF: C14H16ClN3O4S2 FW: N 389.9 H2N H Purity: ≥95% S S Stability: ≥2 years at -20°C OO OO Supplied as: A crystalline solid λ UV/Vis.: max: 226, 271, 317 nm Laboratory Procedures For long term storage, we suggest that cyclothiazide be stored as supplied at -20°C. It should be stable for at least two years. Cyclothiazide is supplied as a crystalline solid. A stock solution may be made by dissolving the cyclothiazide in the solvent of choice. Cyclothiazide is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide (DMF), which should be purged with an inert gas. The solubility of cyclothiazide in ethanol is approximately 2 mg/ml and approximately 10 mg/ml in DMSO and DMF. Cyclothiazide is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, cyclothiazide should first be dissolved in DMF and then diluted with the aqueous buffer of choice. Cyclothiazide has a solubility of approximately 0.5 mg/ml in a 1:1 solution of DMF:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day. Receptors for AMPA are ionotropic glutamate receptors with critical roles in neurological development and function.1-3 Cyclothiazide is a benzothiadiazide that acts as a potentiator of AMPA receptors, positively modulating its response to 4-6 glutamic acid (EC50 = 3.8 µM).
    [Show full text]
  • 2021 Equine Prohibited Substances List
    2021 Equine Prohibited Substances List . Prohibited Substances include any other substance with a similar chemical structure or similar biological effect(s). Prohibited Substances that are identified as Specified Substances in the List below should not in any way be considered less important or less dangerous than other Prohibited Substances. Rather, they are simply substances which are more likely to have been ingested by Horses for a purpose other than the enhancement of sport performance, for example, through a contaminated food substance. LISTED AS SUBSTANCE ACTIVITY BANNED 1-androsterone Anabolic BANNED 3β-Hydroxy-5α-androstan-17-one Anabolic BANNED 4-chlorometatandienone Anabolic BANNED 5α-Androst-2-ene-17one Anabolic BANNED 5α-Androstane-3α, 17α-diol Anabolic BANNED 5α-Androstane-3α, 17β-diol Anabolic BANNED 5α-Androstane-3β, 17α-diol Anabolic BANNED 5α-Androstane-3β, 17β-diol Anabolic BANNED 5β-Androstane-3α, 17β-diol Anabolic BANNED 7α-Hydroxy-DHEA Anabolic BANNED 7β-Hydroxy-DHEA Anabolic BANNED 7-Keto-DHEA Anabolic CONTROLLED 17-Alpha-Hydroxy Progesterone Hormone FEMALES BANNED 17-Alpha-Hydroxy Progesterone Anabolic MALES BANNED 19-Norandrosterone Anabolic BANNED 19-Noretiocholanolone Anabolic BANNED 20-Hydroxyecdysone Anabolic BANNED Δ1-Testosterone Anabolic BANNED Acebutolol Beta blocker BANNED Acefylline Bronchodilator BANNED Acemetacin Non-steroidal anti-inflammatory drug BANNED Acenocoumarol Anticoagulant CONTROLLED Acepromazine Sedative BANNED Acetanilid Analgesic/antipyretic CONTROLLED Acetazolamide Carbonic Anhydrase Inhibitor BANNED Acetohexamide Pancreatic stimulant CONTROLLED Acetominophen (Paracetamol) Analgesic BANNED Acetophenazine Antipsychotic BANNED Acetophenetidin (Phenacetin) Analgesic BANNED Acetylmorphine Narcotic BANNED Adinazolam Anxiolytic BANNED Adiphenine Antispasmodic BANNED Adrafinil Stimulant 1 December 2020, Lausanne, Switzerland 2021 Equine Prohibited Substances List . Prohibited Substances include any other substance with a similar chemical structure or similar biological effect(s).
    [Show full text]